The global Adrenocortical Carcinoma Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The adrenocortical carcinoma drugs market has recorded the development of several advanced imaging techniques, which are non-invasive and exhibit enhanced diagnostic accuracy in the detection of adrenal lesions.
This report aims to provide a comprehensive presentation of the global market for Adrenocortical Carcinoma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adrenocortical Carcinoma Drugs. This report contains market size and forecasts of Adrenocortical Carcinoma Drugs in global, including the following market information:
Global Adrenocortical Carcinoma Drugs Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
For instance, unenhanced computed tomography adrenal densitometry is used to differentiate adrenal adenomas from malignant lesions based on the presence of intracellular lipids. A combination of positron emission tomography/computed tomography is also gaining popularity among end-users for the identification of malignant and benign lesions. Similarly, multiphase computed tomography technique is being used to calculate absolute and relative percentage washout, and thereby, differentiate between benign and malignant lesions.
We surveyed the Adrenocortical Carcinoma Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Adrenocortical Carcinoma Drugs Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Adrenocortical Carcinoma Drugs Market Segment Percentages, by Type, 2022 (%)
- Chemotherapy
- Targeted therapy
Global Adrenocortical Carcinoma Drugs Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Adrenocortical Carcinoma Drugs Market Segment Percentages, by Application, 2022 (%)
- Hospital
- Research institute
- Clinic
- Other
Global Adrenocortical Carcinoma Drugs Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Adrenocortical Carcinoma Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Adrenocortical Carcinoma Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Adrenocortical Carcinoma Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Laboratoire HRA Pharma SAS
- Progenics Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Adrenocortical Carcinoma Drugs, market overview.
Chapter 2: Global Adrenocortical Carcinoma Drugs market size in revenue.
Chapter 3: Detailed analysis of Adrenocortical Carcinoma Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Adrenocortical Carcinoma Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Adrenocortical Carcinoma Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Adrenocortical Carcinoma Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Adrenocortical Carcinoma Drugs Overall Market Size
2.1 Global Adrenocortical Carcinoma Drugs Market Size: 2022 VS 2030
2.2 Global Adrenocortical Carcinoma Drugs Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Adrenocortical Carcinoma Drugs Players in Global Market
3.2 Top Global Adrenocortical Carcinoma Drugs Companies Ranked by Revenue
3.3 Global Adrenocortical Carcinoma Drugs Revenue by Companies
3.4 Top 3 and Top 5 Adrenocortical Carcinoma Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Adrenocortical Carcinoma Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Adrenocortical Carcinoma Drugs Players in Global Market
3.6.1 List of Global Tier 1 Adrenocortical Carcinoma Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Adrenocortical Carcinoma Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Adrenocortical Carcinoma Drugs Market Size Markets, 2022 & 2030
4.1.2 Chemotherapy
4.1.3 Targeted therapy
4.2 By Type - Global Adrenocortical Carcinoma Drugs Revenue & Forecasts
4.2.1 By Type - Global Adrenocortical Carcinoma Drugs Revenue, 2018-2023
4.2.2 By Type - Global Adrenocortical Carcinoma Drugs Revenue, 2024-2030
4.2.3 By Type - Global Adrenocortical Carcinoma Drugs Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Adrenocortical Carcinoma Drugs Market Size, 2022 & 2030
5.1.2 Hospital
5.1.3 Research institute
5.1.4 Clinic
5.1.5 Other
5.2 By Application - Global Adrenocortical Carcinoma Drugs Revenue & Forecasts
5.2.1 By Application - Global Adrenocortical Carcinoma Drugs Revenue, 2018-2023
5.2.2 By Application - Global Adrenocortical Carcinoma Drugs Revenue, 2024-2030
5.2.3 By Application - Global Adrenocortical Carcinoma Drugs Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Adrenocortical Carcinoma Drugs Market Size, 2022 & 2030
6.2 By Region - Global Adrenocortical Carcinoma Drugs Revenue & Forecasts
6.2.1 By Region - Global Adrenocortical Carcinoma Drugs Revenue, 2018-2023
6.2.2 By Region - Global Adrenocortical Carcinoma Drugs Revenue, 2024-2030
6.2.3 By Region - Global Adrenocortical Carcinoma Drugs Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Adrenocortical Carcinoma Drugs Revenue, 2018-2030
6.3.2 US Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.3.3 Canada Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.3.4 Mexico Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Adrenocortical Carcinoma Drugs Revenue, 2018-2030
6.4.2 Germany Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.4.3 France Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.4.4 U.K. Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.4.5 Italy Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.4.6 Russia Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.4.7 Nordic Countries Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.4.8 Benelux Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Adrenocortical Carcinoma Drugs Revenue, 2018-2030
6.5.2 China Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.5.3 Japan Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.5.4 South Korea Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.5.5 Southeast Asia Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.5.6 India Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Adrenocortical Carcinoma Drugs Revenue, 2018-2030
6.6.2 Brazil Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.6.3 Argentina Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Adrenocortical Carcinoma Drugs Revenue, 2018-2030
6.7.2 Turkey Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.7.3 Israel Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.7.4 Saudi Arabia Adrenocortical Carcinoma Drugs Market Size, 2018-2030
6.7.5 UAE Adrenocortical Carcinoma Drugs Market Size, 2018-2030
7 Adrenocortical Carcinoma Drugs Companies Profiles
7.1 Bristol-Myers Squibb Co.
7.1.1 Bristol-Myers Squibb Co. Company Summary
7.1.2 Bristol-Myers Squibb Co. Business Overview
7.1.3 Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Major Product Offerings
7.1.4 Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Revenue in Global Market (2018-2023)
7.1.5 Bristol-Myers Squibb Co. Key News & Latest Developments
7.2 Eli Lilly and Co.
7.2.1 Eli Lilly and Co. Company Summary
7.2.2 Eli Lilly and Co. Business Overview
7.2.3 Eli Lilly and Co. Adrenocortical Carcinoma Drugs Major Product Offerings
7.2.4 Eli Lilly and Co. Adrenocortical Carcinoma Drugs Revenue in Global Market (2018-2023)
7.2.5 Eli Lilly and Co. Key News & Latest Developments
7.3 Laboratoire HRA Pharma SAS
7.3.1 Laboratoire HRA Pharma SAS Company Summary
7.3.2 Laboratoire HRA Pharma SAS Business Overview
7.3.3 Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Major Product Offerings
7.3.4 Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Revenue in Global Market (2018-2023)
7.3.5 Laboratoire HRA Pharma SAS Key News & Latest Developments
7.4 Progenics Pharmaceuticals Inc.
7.4.1 Progenics Pharmaceuticals Inc. Company Summary
7.4.2 Progenics Pharmaceuticals Inc. Business Overview
7.4.3 Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Major Product Offerings
7.4.4 Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Revenue in Global Market (2018-2023)
7.4.5 Progenics Pharmaceuticals Inc. Key News & Latest Developments
7.5 Teva Pharmaceutical Industries Ltd.
7.5.1 Teva Pharmaceutical Industries Ltd. Company Summary
7.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
7.5.3 Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Major Product Offerings
7.5.4 Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Revenue in Global Market (2018-2023)
7.5.5 Teva Pharmaceutical Industries Ltd. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Adrenocortical Carcinoma Drugs Market Opportunities & Trends in Global Market
Table 2. Adrenocortical Carcinoma Drugs Market Drivers in Global Market
Table 3. Adrenocortical Carcinoma Drugs Market Restraints in Global Market
Table 4. Key Players of Adrenocortical Carcinoma Drugs in Global Market
Table 5. Top Adrenocortical Carcinoma Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Adrenocortical Carcinoma Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Adrenocortical Carcinoma Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Adrenocortical Carcinoma Drugs Product Type
Table 9. List of Global Tier 1 Adrenocortical Carcinoma Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Adrenocortical Carcinoma Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Adrenocortical Carcinoma Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Adrenocortical Carcinoma Drugs Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Adrenocortical Carcinoma Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Adrenocortical Carcinoma Drugs Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Adrenocortical Carcinoma Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Adrenocortical Carcinoma Drugs Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2024-2030
Table 30. Bristol-Myers Squibb Co. Company Summary
Table 31. Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Product Offerings
Table 32. Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Bristol-Myers Squibb Co. Key News & Latest Developments
Table 34. Eli Lilly and Co. Company Summary
Table 35. Eli Lilly and Co. Adrenocortical Carcinoma Drugs Product Offerings
Table 36. Eli Lilly and Co. Adrenocortical Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Eli Lilly and Co. Key News & Latest Developments
Table 38. Laboratoire HRA Pharma SAS Company Summary
Table 39. Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Product Offerings
Table 40. Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Laboratoire HRA Pharma SAS Key News & Latest Developments
Table 42. Progenics Pharmaceuticals Inc. Company Summary
Table 43. Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Product Offerings
Table 44. Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. Progenics Pharmaceuticals Inc. Key News & Latest Developments
Table 46. Teva Pharmaceutical Industries Ltd. Company Summary
Table 47. Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Product Offerings
Table 48. Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Teva Pharmaceutical Industries Ltd. Key News & Latest Developments
List of Figures
Figure 1. Adrenocortical Carcinoma Drugs Segment by Type in 2022
Figure 2. Adrenocortical Carcinoma Drugs Segment by Application in 2022
Figure 3. Global Adrenocortical Carcinoma Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Adrenocortical Carcinoma Drugs Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Adrenocortical Carcinoma Drugs Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Adrenocortical Carcinoma Drugs Revenue in 2022
Figure 8. By Type - Global Adrenocortical Carcinoma Drugs Revenue Market Share, 2018-2030
Figure 9. By Application - Global Adrenocortical Carcinoma Drugs Revenue Market Share, 2018-2030
Figure 10. By Type - Global Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Adrenocortical Carcinoma Drugs Revenue Market Share, 2018-2030
Figure 12. By Application - Global Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Adrenocortical Carcinoma Drugs Revenue Market Share, 2018-2030
Figure 14. By Region - Global Adrenocortical Carcinoma Drugs Revenue Market Share, 2018-2030
Figure 15. By Country - North America Adrenocortical Carcinoma Drugs Revenue Market Share, 2018-2030
Figure 16. US Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Adrenocortical Carcinoma Drugs Revenue Market Share, 2018-2030
Figure 20. Germany Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 21. France Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Adrenocortical Carcinoma Drugs Revenue Market Share, 2018-2030
Figure 28. China Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 32. India Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Adrenocortical Carcinoma Drugs Revenue Market Share, 2018-2030
Figure 34. Brazil Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Adrenocortical Carcinoma Drugs Revenue Market Share, 2018-2030
Figure 37. Turkey Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Adrenocortical Carcinoma Drugs Revenue, (US$, Mn), 2018-2030
Figure 41. Bristol-Myers Squibb Co. Adrenocortical Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Eli Lilly and Co. Adrenocortical Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Laboratoire HRA Pharma SAS Adrenocortical Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Progenics Pharmaceuticals Inc. Adrenocortical Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Teva Pharmaceutical Industries Ltd. Adrenocortical Carcinoma Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
